Dextromethorphan/quinidine

Not to be confused with Deudextromethorphan/quinidine.
Dextromethorphan/quinidine
Combination of
DextromethorphanSigma-1 receptor agonist, NMDA receptor antagonist, serotonin–norepinephrine reuptake inhibitor
QuinidineAntiarrhythmic agent, CYP2D6 inhibitor
Clinical data
Trade namesNuedexta
Other namesAVP-923; DXM/quinidine
AHFS/Drugs.comMonograph
MedlinePlusa611048
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailabilitydextromethorphan 11%, quinidine 70-80%. Food has no effect on absorption.
MetabolismLiver, extensive. Dextromethorphan is catalyzed by CYP2D6. Quinidine is metabolized by CYP3A4 and competitively inhibits the metabolism of dextromethorphan to increase and prolong plasma concentrations of dextromethorphan
Elimination half-lifedextromethorphan 13h, quinidine 7h
Excretionquinidine 5-20%
Identifiers
CAS Number
KEGG

Dextromethorphan/quinidine, sold under the brand name Nuedexta, is a fixed-dose combination medication for the treatment of pseudobulbar affect (PBA).[2][3] It contains dextromethorphan (DXM) and the class I antiarrhythmic agent quinidine.[2]

Dextromethorphan/quinidine was approved for medical use in the United States in October 2010, and is marketed by Avanir Pharmaceuticals.[4]

  1. ^ "Dextromethorphan / quinidine (Nuedexta) Use During Pregnancy". Drugs.com. 21 August 2019. Retrieved 13 September 2020.
  2. ^ a b "Nuedexta- dextromethorphan hydrobromide and quinidine sulfate capsule, gelatin coated". DailyMed. 23 June 2019. Retrieved 23 October 2020.
  3. ^ "Highlights for prescribing information" (PDF). fda.gov. 2019. Retrieved 11 April 2023.
  4. ^ "Drug Approval Package: Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) Capsules NDA #021879". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 23 October 2020.